<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="30142b39-1441-7d9f-e063-6394a90ac169"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Ciprofloxacin Ophthalmic Solution, USP 0.3%</content>
      <br/>
Sterile
</title>
   <effectiveTime value="20250311"/>
   <setId root="74af98f1-eb6d-473b-94a9-67920dba8c3d"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="051627256"/>
            <name>Advagen Pharma Limited</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="30143437-a174-81df-e063-6394a90ab70e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250311"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72888-102" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CIPROFLOXACIN HYDROCHLORIDE</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>CIPROFLOXACIN HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4BA73M5E37" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CIPROFLOXACIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5E8K9I0O4U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CIPROFLOXACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72888-102-21" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220316"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72888-102-22" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220316"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72888-102-23" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220316"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075928" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220316"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Ld0fe1f86-63e5-4a9c-83a8-a69b31ab2ab5">
               <id root="30142b39-1442-7d9f-e063-6394a90ac169"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION:</title>
               <text>
                  <paragraph>Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid. It is a faint to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C
 
  <sub>17</sub>H
 
  <sub>18</sub>FN
 
  <sub>3</sub>O
 
  <sub>3</sub>•HCL•H
 
  <sub>2</sub>O and its chemical structure is as follows:

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0"/>
                  </paragraph>
                  <paragraph>Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position.</paragraph>
                  <paragraph/>
                  <paragraph>Each mL of ciprofloxacin ophthalmic solution contains:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Active:</content>Ciprofloxacin hydrochloride 3.5 mg equivalent to 3mg base.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative:</content>Benzalkonium chloride 0.006%.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactives:</content>Acetic acid, edetate disodium 0.05%, mannitol  4.6%, Sodium acetate, hydrochloric acid and/or sodium hydroxide (to adjust pH) and water for injection. The pH is between 3.5 to 5.5 and the osmolality is between 290 to 300 mOsms/kg.

 </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20220316"/>
               <component>
                  <observationMedia ID="MM0">
                     <text>Ciprofloxacin Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprofloxacin-ophthalmic-solution-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L933ce46f-bf96-4ee0-bfea-135ed02df426">
               <id root="30142b39-1443-7d9f-e063-6394a90ac169"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY:</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Systemic Absorption:</content>A systemic absorption study was performed in which ciprofloxacin ophthalmic solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. The maximum reported plasma concentration of ciprofloxacin was less than 5 ng/mL. The mean concentration was usually less than 2.5 ng/mL.

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Microbiology</content>: Ciprofloxacin has
 
  <content styleCode="italics">in vitro</content>activity against a wide range of gram-negative and gram- positive organisms. The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase which is needed for the synthesis of bacterial DNA.

 </paragraph>
                  <paragraph/>
                  <paragraph>Ciprofloxacin has been shown to be active against most strains of the following organisms both
 
  <content styleCode="italics">in vitro</content>and in clinical infections (SEE
 
  <content styleCode="bold">
                        <linkHtml href="#L6c15598d-c402-46bd-ac78-8fe3c06c6ca3">INDICATIONS AND USAGE</linkHtml>
                     </content>section):

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Gram-Positive:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Staphylococcus aureus</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Staphylococcus epidermidis</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Streptococcus pneumoniae</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Streptococcus</content>(Viridans Group)

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Gram-Negative:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Haemophilus influenzae</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Pseudomonas aeruginosa</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Serratia marcescens</content>
                  </paragraph>
                  <paragraph>Ciprofloxacin has been shown to be active
 
  <content styleCode="italics">in vitro</content>against most strains of the following organisms, however,
 
  <content styleCode="italics">the clinical significance of these data is unknown:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Gram-Positive:</content>
                     <br/>
                     <content styleCode="italics">Enterococcus faecalis</content>(Many strains are only moderately susceptible) 
  <br/>
                     <content styleCode="italics">Staphylococcus haemolyticus</content>
                     <br/>
                     <content styleCode="italics">Staphylococcus hominis</content>
                     <br/>
                     <content styleCode="italics">Staphylococcus saprophyticus</content>
                     <br/>
                     <content styleCode="italics">Streptococcus pyogenes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Gram-Negative:</content>
                     <br/>
                     <content styleCode="italics">Acinetobacter calcoaceticus</content>
                     <content styleCode="italics">             Escherichia coli</content>
                     <content styleCode="italics">                              Proteus mirabilis</content>
                     <br/>
                     <content styleCode="italics">subsp. anitratus</content>
                     <content styleCode="italics">                                Haemophilus ducreyi</content>
                     <content styleCode="italics">                      Proteus vulgaris</content>
                     <br/>
                     <content styleCode="italics">Aeromonas caviae</content>
                     <content styleCode="italics">                           Haemophilus parainfluenzae</content>
                     <content styleCode="italics">           Providencia rettgeri</content>
                     <br/>
                     <content styleCode="italics">Aeromonas hydrophila</content>
                     <content styleCode="italics">                    Kiebsiella pneumoniae</content>
                     <content styleCode="italics">                    Providencia stuartii</content>
                     <br/>
                     <content styleCode="italics">Brucella melitensis</content>
                     <content styleCode="italics">                          Klebsiella oxytoca</content>
                     <content styleCode="italics">                           Salmonella enteritidis</content>
                     <br/>
                     <content styleCode="italics">Campylobacter coli</content>
                     <content styleCode="italics">                        Legionella pneumophila</content>
                     <content styleCode="italics">                  Salmonella typhi</content>
                     <br/>
                     <content styleCode="italics">Campylobacter jejuni</content>
                     <content styleCode="italics">                    Moraxella (Branhamella)</content>
                     <content styleCode="italics">                Shigella sonneii</content>
                     <br/>
                     <content styleCode="italics">Citrobacter diversus</content>
                     <content styleCode="italics">                             catarrhalis</content>
                     <content styleCode="italics">                                 Shigella flexneri</content>
                     <br/>
                     <content styleCode="italics">Citrobacter freundii</content>
                     <content styleCode="italics">                       Morganella morganii</content>
                     <content styleCode="italics">                     Vibrio cholerae</content>
                     <br/>
                     <content styleCode="italics">Edwardsiella tarda</content>
                     <content styleCode="italics">                        Neisseria gonorrhoeae</content>
                     <content styleCode="italics">                   Vibrio parahaemolyticus</content>
                     <br/>
                     <content styleCode="italics">Enterobacter aerogenes</content>
                     <content styleCode="italics">                Neisseria meningitidis</content>
                     <content styleCode="italics">                    Vibrio vulnificus</content>
                     <br/>
                     <content styleCode="italics">Enterobacter cloacae</content>
                     <content styleCode="italics">                    Pasteurella multocida</content>
                     <content styleCode="italics">                    Yersinia enterocolitica</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Other Organisms:</content>
                     <content styleCode="italics">Chlamydia trachomatis</content>(only moderately susceptible) and
 
  <content styleCode="italics">Mycobacterium tuberculosis</content>(only moderately susceptible).

 </paragraph>
                  <paragraph/>
                  <paragraph>Most strains of
 
  <content styleCode="italics">Pseudomonas cepacia</content>and some strains of
 
  <content styleCode="italics">Pseudomonas maltophilia</content>are resistant to ciprofloxacin as are most anaerobic bacteria, including
 
  <content styleCode="italics">Bacteroides fragilis</content>and
 
  <content styleCode="italics">Clostridium difficile</content>. The minimal bactericidal concentration (MBC) generally does not exceed the minimal inhibitory concentration (MIC) by more than a factor of 2. Resistance to ciprofloxacin
 
  <content styleCode="italics">in vitro</content>usually develops slowly (multiple-step mutation).

 </paragraph>
                  <paragraph/>
                  <paragraph>Ciprofloxacin does not cross-react with other antimicrobial agents such as beta-lactams or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20220316"/>
               <component>
                  <section ID="L990e955c-3859-46ce-8b12-25f73063466d">
                     <id root="30142b39-1444-7d9f-e063-6394a90ac169"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>Clinical Studies:</title>
                     <text>
                        <paragraph>Following therapy with ciprofloxacin ophthalmic solution, 76% of the patients with corneal ulcers and positive bacterial cultures were clinically cured and complete re-epithelialization occurred in about 92% of the ulcers.</paragraph>
                        <paragraph/>
                        <paragraph>In 3 and 7 day multicenter clinical trials, 52% of the patients with conjunctivitis and positive conjunctival cultures were clinically cured and 70-80% had all causative pathogens eradicated by the end of treatment.</paragraph>
                        <paragraph/>
                        <paragraph>In a randomized, double-masked, multicenter, parallel-group clinical trial of pediatric patients with bacterial conjunctivitis, between birth and 31 days of age, patients were dosed with ciprofloxacin or another anti-infective agent. Clinical outcomes for the trial demonstrated a clinical cure rate of 80% at Day 9 anda microbiological eradication success rate of 85% at Day 9.</paragraph>
                        <paragraph>Please note that microbiologic eradication does not always correlate with clinical outcome in anti- infective trials.</paragraph>
                     </text>
                     <effectiveTime value="20220316"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L6c15598d-c402-46bd-ac78-8fe3c06c6ca3">
               <id root="30142b39-1445-7d9f-e063-6394a90ac169"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE:</title>
               <text>
                  <paragraph>Ciprofloxacin ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Corneal Ulcers:</content>
                     <content styleCode="italics">    Pseudomonas aeruginosa</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">                              Serratia marcescens</content>*

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">                              Staphylococcus aureus</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">                              Staphylococcus epidermidis</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">                              Streptococcus pneumoniae</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">                              Streptococcus</content>(Viridans Group) *

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Conjunctivitis:   </content>
                     <content styleCode="italics">  Haemophilus influenzae</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">                             Staphylococcus aureus</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">                             Staphylococcus epidermidis</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">                             Streptococcus pneumoniae</content>
                  </paragraph>
                  <paragraph>*Efficacy for this organism was studied in fewer than 10 infections.</paragraph>
               </text>
               <effectiveTime value="20220316"/>
            </section>
         </component>
         <component>
            <section ID="L234ec311-c161-4888-8250-bd3884f43402">
               <id root="30142b39-1446-7d9f-e063-6394a90ac169"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS:</title>
               <text>
                  <paragraph>A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.</paragraph>
               </text>
               <effectiveTime value="20220316"/>
            </section>
         </component>
         <component>
            <section ID="L9fa9f865-b566-4aca-9f49-5c514251d788">
               <id root="30142b39-1447-7d9f-e063-6394a90ac169"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS:</title>
               <text>
                  <paragraph>NOT FOR INJECTION INTO THE EYE.</paragraph>
                  <paragraph>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria,and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated.</paragraph>
                  <paragraph/>
                  <paragraph>Remove contact lenses before using.</paragraph>
               </text>
               <effectiveTime value="20220316"/>
            </section>
         </component>
         <component>
            <section ID="Lb92a4890-31dd-41f2-a113-02154134115c">
               <id root="30142b39-1448-7d9f-e063-6394a90ac169"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS:</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">General:</content>As with other antibacterial preparations, prolonged use of ciprofloxacin may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.

 </paragraph>
                  <paragraph/>
                  <paragraph>Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction.</paragraph>
                  <paragraph/>
                  <paragraph>In clinical studies of patients with bacterial corneal ulcer, a white crystalline precipitate located in the superficial portion of the corneal defect was observed in 35 (16.6%) of 210 patients. The onset of the precipitate was within 24 hours to 7 days after starting therapy. In one patient, the precipitate was immediately irrigated out upon its appearance. In 17 patients, resolution of the precipitate was seen in 1 to8 days (seven within the first 24 to 72 hours), in five patients, resolution was noted in 10 to 13 days. In nine patients, exact resolution days were unavailable; however, at follow-up examinations, 18 to 44 days after onset of the event, complete resolution of the precipitate was noted. In three patients, outcome information was unavailable. The precipitate did not preclude continued use of ciprofloxacin, nor did it adversely affect the clinical course of the ulcer or visual outcome. (SEE
 
  <content styleCode="bold">
                        <linkHtml href="#L45f0233c-e99d-4af0-a4e0-d4e004372b10">ADVERSE REACTIONS</linkHtml>
                     </content>).

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Information for patients:</content>Do not touch dropper tip to any surface, as this may contaminate the solution.

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Drug Interactions:</content>Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</content>Eight
 
  <content styleCode="italics">in vitro</content>mutagenicity tests have been conducted with ciprofloxacin and the test results are listed below:

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="italics">             Salmonella</content>/Microsome Test (Negative) 
  <br/>
                     <content styleCode="italics">             E. coli</content>DNA Repair Assay (Negative) 
  <br/>               Mouse Lymphoma Cell Forward Mutation Assay (Positive) 
  <br/>               Chinese Hamster V79 Cell HGPRT Test (Negative) 
  <br/>               Syrian Hamster Embryo Cell Transformation Assay (Negative) 
  <br/>
                     <content styleCode="italics">Saccharomyces cerevisiae</content>Point Mutation Assay (Negative) 
  <br/>
                     <content styleCode="italics">Saccharomyces cerevisiae</content>Mitotic Crossover and Gene Conversion Assay (Negative) 
  <br/>               Rat Hepatocyte DNA Repair Assay (Positive)

 </paragraph>
                  <paragraph>Thus, two of the eight tests were positive, but the results of the following three
 
  <content styleCode="italics">in vivo</content>test systems gave negative results:

 </paragraph>
                  <paragraph/>
                  <paragraph>             Rat Hepatocyte DNA Repair Assay 
  <br/>               Micronucleus Test (Mice) 
  <br/>               Dominant Lethal Test (Mice)
 </paragraph>
                  <paragraph/>
                  <paragraph>Long term carcinogenicity studies in mice and rats have been completed. After daily oral dosing for up to two years, there is no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Pregnancy:</content>Reproduction studies have been performed in rats and mice at doses up to six times the usual daily human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to ciprofloxacin. In rabbits, as with most antimicrobial agents, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in maternal weight loss and an increased incidence of abortion. No teratogenicity was observed at either dose. After intravenous administration, at doses up to 20 mg/kg, no maternal toxicity was produced and no embryotoxicity or teratogenicity was observed. There are no adequate and well controlled studies in pregnant women. 
  <br/>  Ciprofloxacin Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Nursing Mothers:</content>It is not known whether topically applied ciprofloxacin is excreted in human milk; however, it is known that orally administered ciprofloxacin is excreted in the milk of lactating rats and oral ciprofloxacin has been reported in human breast milk after a single 500 mg dose. Caution should be exercised when Ciprofloxacin Ophthalmic Solution is administered to a nursing mother.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pediatric Use:</content>
                  </paragraph>
                  <paragraph>The safety and effectiveness of ciprofloxacin ophthalmic solution 0.3% have been established in all ages. Use of ciprofloxacin is supported by evidence from adequate and well controlled studies of ciprofloxacin in adults, children and neonates
 
  <content styleCode="italics">[see
  
   <linkHtml href="#L990e955c-3859-46ce-8b12-25f73063466d">Clinical Studies</linkHtml>].
 
  </content>Although ciprofloxacin and other quinolones cause arthropathy in immature animals after oral administration, topical ocular administration of ciprofloxacin to immature animals did not cause any arthropathy and there is no evidence that the ophthalmic dosage form has any effect on the weight bearing joints.

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Geriatric Use:</content>No overall differences in safety or effectiveness have been observed between elderly and younger patients.

 </paragraph>
               </text>
               <effectiveTime value="20220316"/>
            </section>
         </component>
         <component>
            <section ID="L45f0233c-e99d-4af0-a4e0-d4e004372b10">
               <id root="30142b39-1449-7d9f-e063-6394a90ac169"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS:</title>
               <text>
                  <paragraph>The most frequently reported drug related adverse reaction was local burning or discomfort. In corneal ulcer studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients (SEE
 
  <content styleCode="bold">
                        <linkHtml href="#Lb92a4890-31dd-41f2-a113-02154134115c">PRECAUTIONS</linkHtml>
                     </content>). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and a bad taste following instillation. Additional events occurring in less than 1% of patients included corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Advagen Pharma Ltd, at 866-488-0312 or FDA at 1-800-FDA-1088 or
  
   <content styleCode="italics">www.fda.gov/medwatch</content>.
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20220316"/>
            </section>
         </component>
         <component>
            <section ID="L33e9a9b0-6eee-44c7-94c8-d508eac26b56">
               <id root="30142b39-144a-7d9f-e063-6394a90ac169"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE:</title>
               <text>
                  <paragraph>A topical overdose of ciprofloxacin ophthalmic solution may be flushed from the eye(s) with warm tap water.</paragraph>
               </text>
               <effectiveTime value="20220316"/>
            </section>
         </component>
         <component>
            <section ID="L7ece5034-b9de-4ba2-8bac-cd9da0a9d69a">
               <id root="30142b39-144b-7d9f-e063-6394a90ac169"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION:</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Corneal Ulcers:</content>The recommended dosage regimen for the treatment of
 
  <content styleCode="bold">corneal ulcers</content>is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Bacterial Conjunctivitis:</content>The recommended dosage regimen for the treatment of
 
  <content styleCode="bold">bacterial conjunctivitis</content>is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.

 </paragraph>
               </text>
               <effectiveTime value="20220316"/>
            </section>
         </component>
         <component>
            <section ID="L55914216-e057-4dc1-a841-571743e0c637">
               <id root="30142b39-144c-7d9f-e063-6394a90ac169"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">How Supplied:</content>As a sterile ophthalmic solution: 2.5 mL, 5 mL and 10 mL in translucent LDPE bottle, translucent LDPE nozzle and tan coloured polypropylene closure.

 </paragraph>
                  <paragraph>        2.5 mL - NDC 72888-102-21</paragraph>
                  <paragraph>        5 mL - NDC 72888-102-22</paragraph>
                  <paragraph>        10 mL - NDC 72888-102-23</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content>Store at 2°C to 25°C (36°F to 77°F). Protect from light.

 </paragraph>
               </text>
               <effectiveTime value="20220316"/>
               <component>
                  <section ID="L49c3dd05-18b3-49ce-bc0f-0efbc103afad">
                     <id root="30142b39-144d-7d9f-e063-6394a90ac169"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>ANIMAL PHARMACOLOGY:</title>
                     <text>
                        <paragraph>Ciprofloxacin and related drugs have been shown to cause arthropathy in immature animals of most species tested following oral administration. However, a one-month topical ocular study using immature Beagle dogs did not demonstrate any articular lesions.</paragraph>
                        <paragraph/>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">Distributed by:</content>
                        </paragraph>
                        <paragraph>Advagen Pharma Ltd.,</paragraph>
                        <paragraph>East Windsor, NJ 08520, USA.</paragraph>
                        <paragraph>Rev. 01, 09/2024</paragraph>
                     </text>
                     <effectiveTime value="20220316"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L90ab8b13-aff6-432f-ac40-a2a144fc7a9b">
               <id root="30142b39-144e-7d9f-e063-6394a90ac169"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Carton</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>
                     <content styleCode="bold">Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Container</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>
                     <content styleCode="bold">Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Carton</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>
                     <content styleCode="bold">Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Container</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph>
                     <content styleCode="bold">Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Carton</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph>
                     <content styleCode="bold">Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Container</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20220316"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Carton </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprofloxacin-ophthalmic-solution-2pt5ml-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Container </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprofloxacin-ophthalmic-solution-2pt5ml-container.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Carton </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprofloxacin-ophthalmic-solution-5ml-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Container </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprofloxacin-ophthalmic-solution-5ml-container.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Carton </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprofloxacin-ophthalmic-solution-10ml-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Container </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprofloxacin-ophthalmic-solution-10ml-container.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>